Oxford Biomedica notes Japanese approval of Kymriah, the first CAR-T cell therapy
OXFORD, UK: Oxford Biomedica plc, a leading gene and cell therapy group, notes an announcement by Novartis that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Kymriah® (tisagenlecleucel)…